Analyst Price Target is $5.00
▲ +293.70% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. The average price target is $5.00, with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a 293.70% upside from the last price of $1.27.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Citius Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.